Current landscape and tailored management of immune-related adverse events
Unprecedented advances have been made in immune checkpoint inhibitors (ICIs) in the treatment of cancer. However, the overall benefits from ICIs are impaired by the increasing incidence of immune-related adverse events (irAEs). Although several factors and mechanisms have been proposed in the develo...
Main Authors: | Wenhui Liu, Zhiying Luo, Yiping Liu, Bao Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1078338/full |
Similar Items
-
Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy
by: Jianquan Luo, et al.
Published: (2022-09-01) -
Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01) -
Advances in Predictive Research of Immune Checkpoint Inhibitors-related
Adverse Events
by: Jing ZHANG, et al.
Published: (2023-10-01) -
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01) -
Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
by: Lingli Luo, et al.
Published: (2023-04-01)